Rank + list placement
Show exactly where the name sits in the monthly product.
Include list, rank, probability, quant score, and edition month.
Monthly product upgrade
Stock Thesis Template for Every Ranked Name
A repeatable package that turns each Upside Ranks ticker from a scored list entry into a publishable research card: rank, catalyst, key numbers, bull path, bear case, source links, and what would change our mind.
One-line thesis
Force the idea into a clean investment claim before adding detail.
One sentence only; no generic “AI winner” language.
Why now
Explain the current catalyst, not just the long-term story.
Must identify a near-term trigger: earnings, guidance, orders, product cycle, capex cycle, or technical setup.
Key numbers
Anchor the thesis in hard data instead of vibes.
Use current market cap/price, score, target-path math, and at least two material operating numbers when available.
Bull case / path to target
Make the upside path explicit and falsifiable.
Use the relevant +35%, 2x, or 5x path from the monthly data record; do not imply it is a base case.
Bear case
Show what could break the idea before readers discover it for us.
Must include the fastest thesis-breaker and whether the risk is valuation, execution, demand, concentration, or balance sheet.
What would change our mind
Create a clean future update trigger for the next monthly refresh.
Name one upgrade trigger and one cut/demotion trigger.
Source links
Make every material claim auditable.
Minimum two credible links; prefer filings, company IR, transcripts, or high-quality financial data.
Copy-ready shell
Blank thesis template
Use once per ticker before the monthly publish gate.
[TICKER] — [Company] · [List] rank #[Rank] · [Edition]
- •Rank + score: [List], #[Rank], [Probability], quant score [Score]
- •One-line thesis: [One sentence that explains why this stock belongs in the list now]
- •Why now: [Near-term catalyst and timing]
- •Key numbers: [Current price/market cap, relevant growth/margin/order/backlog numbers, target-path math]
- •Bull case / path to target: [What has to happen for +35%, 2x, or 5x]
- •Bear case: [Fastest way the thesis breaks]
- •What would change our mind: [Upgrade trigger] / [Cut or demotion trigger]
- •Sources: [At least two source URLs]
Filled examples
June 2026 sample thesis cards
July 2026· 2x rank #1
CRDO · Credo Technology Group Holding Ltd
Credo is the highest-conviction 2x name because it attacks a real AI cluster bottleneck: moving data inside scale-out systems without blowing up power budgets.
Rank + score
2x rank #1; probability 14.6%; quant score 82.6.
Why now
AEC unit ramp at hyperscale AI data-center customers
Key numbers
- • Current data price: $259.09
- • Market cap field: $48.3B
- • July quant market cap: $48.3B
- • Goldilox bull market cap: $85.0B
- • BRRR list placement: 35% rank #2 (quant score 88.3), 2x rank #1 (quant score 82.6), 5x rank #5 (quant score 85.8)
Bull case / path to target
A 2x needs three things: FY2027 revenue visibility moving toward the $2.5B-$3.0B zone, sustained gross margins above 60%, and evidence that multiple hyperscaler programs are ramping. If those show up together, Credo can be valued as a core AI connectivity platform rather than a single-cycle AEC winner.
Bear case
The biggest risk is concentration. Two customers drove 87% of Q3 FY2026 revenue, so a pause, design loss, or inventory digestion event could break the thesis fast. The valuation also leaves little room for execution mistakes.
What would change our mind
Upgrade: SEC filing attributes the revenue increase primarily to higher AEC shipments.
Cut/demote: Demote if customer concentration does not broaden beyond two hyperscalers by the next two reporting cycles.
July 2026· 35% rank #6
NVDA · NVIDIA Corporation
NVIDIA remains the cleanest mega-cap expression of the AI compute bottleneck, but this is no longer a discovery story — it is an expectations and revision story.
Rank + score
35% rank #6; probability 37.1%; quant score 78.4.
Why now
Record Q1 FY2027 revenue and Data Center revenue, with Q2 revenue guide stepping up again to $91B.
Key numbers
- • Current data price: $197.58
- • Market cap field: $4.79T
- • July quant market cap: $4.79T
- • Goldilox bull market cap: $6.90T
- • BRRR list placement: 35% rank #6 (quant score 78.4)
Bull case / path to target
+35% is plausible if Blackwell/Rubin demand keeps exceeding supply, Q2 guidance proves conservative, inference revenue broadens beyond training clusters, and the market keeps raising out-year earnings estimates. This is a high-quality, high-expectation setup: the stock needs continued upside revisions, not just another strong quarter.
Bear case
The risk is not business quality; it is the altitude of expectations. A pause in hyperscaler capex, export-control pressure, faster custom ASIC substitution, or even modest margin compression could make strong execution insufficient for another +35% move.
What would change our mind
Upgrade: Blackwell, Vera Rubin, NVLink Fusion, optics partnerships, and Dynamo inference software deepen the full-stack AI factory moat.
Cut/demote: Sequential Data Center growth slows sharply without a clear supply-transition explanation.
July 2026· 5x rank #2
AEHR · Aehr Test Systems
Aehr is the purest small-cap test-equipment moonshot in the June list.
Rank + score
5x rank #2; probability 8.7%; quant score 89.1.
Why now
April 16, 2026 record $41M follow-on production order from lead hyperscale customer for package-level burn-in of custom AI processor ASICs used in data-center training and inference workloads.
Key numbers
- • Current data price: $84.43
- • Market cap field: $2.7B
- • July quant market cap: $2.7B
- • Goldilox bull market cap: $7.5B
- • BRRR list placement: 2x rank #5 (quant score 75.3), 5x rank #2 (quant score 89.1)
Bull case / path to target
A 5x requires Aehr to move from niche supplier to critical test-equipment beneficiary across AI-adjacent silicon carbide, photonics, and advanced semiconductor reliability markets. The base bull case is smaller than 5x; the 5x case needs a new order cycle and broader customer adoption.
Bear case
Aehr is small, order-driven, and customer-concentrated. Revenue can be lumpy, orders can slip, and weak FY2027 conversion would quickly undermine the thesis. This is risk-capital only, not a quality compounder.
What would change our mind
Upgrade: Second-half FY26 bookings exceeded $92M as of April 16, already above the high side of the previously increased $60M-$80M expectation.
Cut/demote: Lead hyperscale AI customer pushes out Sonoma deliveries or next-gen ASIC production.
Publication rule
A ranked name is not ready for the final monthly package until this thesis card, the scoring audit, and the source-confidence gate agree. If the card cannot explain “why now” and “what would change our mind,” the rank needs more research before publication.